PBAC's latest decision on Blinatumomab: Recommended with restriction (2024). Considered for B-cell precursor acute lymphoblastic leukaemia (B-ALL) in complete haematological remission following induction chemotherapy, regardless of measurable residual disease (MRD) status, in the consolidation phase.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
8
first 2015
Submissions
8
2015 → 2024
Eligible population
Newly diagnosed patients with B-cell precursor acute lymphoblastic leukaemia in haematological complete remission, ECOG performance status 0 or 1, with or without measurable residual disease, without CNS or testicular involvement, following intensive combination chemotherapy for initial treatment or salvage therapy.
Therapy area
Haematology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Relapse-free survival
Key trials
E1910
Comparator
standard of care consolidation chemotherapy alone
Economic model
CUA
ICER note
ICER value(s) redacted in the public document; numeric values not stated
ICER (historical)
$45k/QALY–$75k/QALY across 4 submissions (2016–2019) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2015: Noted · Authority Required
Jul 2016: Not recommended · Authority Required — ICER $75k/QALY
Nov 2016: Recommended with restriction · Restricted — ICER $75k/QALY
Jul 2018: Recommended with restriction · Authority Required
Mar 2019: Recommended with restriction · Authority Required — ICER $105k/QALY
May 2019: Recommended with restriction · Restricted